Immunotherapeutic tumor treatment method
US12030940B2 · kind B2 · utility
0Cited by
2References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2018 |
| Grant date | Jul 9, 2024 |
| Priority date | — |
| Expiry date | Jan 18, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2Rβ-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.